Access Vascular
Access Vascular is a privately held medical device company that develops proprietary MIMIX hydrophilic biomaterial vascular access catheters (HydroPICC and HydroMID) for acute care hospitals, reducing catheter-related thrombosis and complications, with FDA-cleared anti-thrombogenic indication and a Medline U.S. distribution partnership.
- Company typePrivate
- Founded2015
- HeadquartersBedford, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Access Vascular does
Access Vascular, Inc. (AVI) is a privately held medical device company founded in 2015 and headquartered at 749 Middlesex Turnpike in Billerica, Massachusetts. The company develops and commercializes vascular access catheters for acute care hospitals, targeting the clinical and economic burden of catheter-related complications — thrombosis, occlusion, infection, and phlebitis — that cost the U.S. healthcare system an estimated $4.5 billion annually. Its customers are large acute care hospitals and health systems, with named deployments including Stillwater Medical Center (Oklahoma) and a large acute care hospital chain in the Northeast using as many as 100 HydroMID lines per month.
The company's product portfolio is built on a proprietary MIMIX hydrophilic biomaterial platform — a composite polyvinyl alcohol and polyacrylic acid hydrogel that absorbs water upon hydration to create a consistently hydrophilic, lubricious catheter surface. This material is designed to repel protein adsorption, reduce bacterial adhesion, and create thromboresistance without drug coatings, fillers, or surface modifications. The commercial line consists of two FDA 510(k)-cleared device families: HydroPICC (peripherally inserted central catheter, 4F single lumen and 5F dual lumen, cleared 2018) and HydroMID (peripherally inserted midline catheter, 4F single lumen, cleared 2021). In October 2025, both product lines received an FDA-cleared anti-thrombogenic indication — reportedly the only drug-free catheters with that designation. Both are offered in Basic and Maximal Barrier Kit configurations.
Access Vascular generates revenue through hardware sales of its catheters to hospitals, distributed via a hybrid model combining a direct enterprise field sales force with a newly signed multi-year co-branding and distribution agreement with Medline that takes effect in late 2026 and provides access to more than 1,600 Prime Vendor customers and 300+ acute care representatives. The company has raised approximately $57M in venture funding across rounds from 2017 through a $22M Series C in October 2023, employs roughly 40 people, and is led by founder/CEO James Biggins with CCO Dennis Byrne heading commercialization.
Access Vascular firmographics
Firmographics- Name
- Access Vascular
- Legal name
- Access Vascular, Inc.
- Website
- https://accessvascularinc.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Access Vascular is a privately held medical device company that develops proprietary MIMIX hydrophilic biomaterial vascular access catheters (HydroPICC and HydroMID) for acute care hospitals, reducing catheter-related thrombosis and complications, with FDA-cleared anti-thrombogenic indication and a Medline U.S. distribution partnership.
- Ownership category
- akta.pro rank
Access Vascular industry classification
Industry- Product category
- Vascular Access Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)
- akta.pro secondary industries
- Infusion Sets, Catheters & Pump Consumables (HLAHAIAH), IV Therapy, Infusion & Fluid Management (Pumps, Catheters, Fluid Sets) (HLAMAFAG)
Keywords
Where Access Vascular is headquartered
LocationHeadquarters
- HQ city
- Bedford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Access Vascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of proprietary vascular access catheters (HydroPICC and HydroMID) to healthcare systems and hospitals through direct sales and distribution partnerships.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Access Vascular product offering
Product offeringCore offering
Access Vascular manufactures and sells proprietary vascular access catheters (HydroPICC and HydroMID) built on its patented MIMIX hydrophilic biomaterial platform. The catheters are FDA-cleared with an anti-thrombogenic indication and are designed to reduce catheter-related complications such as thrombosis, occlusions, and infections compared to standard polyurethane devices. The company sells to acute care hospitals and health systems through direct sales and a Medline distribution partnership.
Product overview
Access Vascular offers a suite of vascular access devices built on its proprietary MIMIX™ hydrophilic biomaterial technology. The product portfolio consists of two core device families: HydroPICC® (peripherally inserted central catheters available in 4F single lumen and 5F dual lumen configurations) and HydroMID® (4F single lumen midline catheter). Both product lines utilize the same MIMIX™ technology platform—a consistently hydrophilic hydrogel material designed to reduce thrombosis, infection, and other vascular access complications. Both device families are available in basic or maximal barrier kit configurations. The technology aims to prevent the foreign body response that typically occurs with standard polyurethane catheters.
Differentiator
Problem solved
Functional benefit
Products and services
- HydroPICC Peripherally inserted central venous catheter (PICC) designed for short- or long-term peripheral access to the central venous system for intravenous therapy. Available in 4 French single lumen and 5 French dual lumen configurations and featuring MIMIX hydrophilic biomaterial technology for thrombosis and complication reduction.
- HydroMID Midline catheter designed for short-term (less than 30 days) peripheral access to the venous system for intravenous therapy. A 4 French single lumen catheter featuring MIMIX hydrophilic biomaterial technology with demonstrated 6x fewer complications than standard polyurethane catheters and a maximum power injection flow rate of 6 ml/sec at 300 psi.
- HydroPICC and HydroMID with Anti-Thrombogenic Indication FDA-cleared anti-thrombogenic version of the HydroPICC and HydroMID catheters, designed to enhance vascular access safety without the associated risks of drug coatings. Indicated for reduction of thrombus formation in indwelling vascular access catheters.
Quantifiable outcome
- 97% less thrombus accumulation compared to standard polyurethane catheters (based on platelet count)
- +6 more outcomes
Companies that use Access Vascular
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Access Vascular technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Access Vascular partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MedlinecoreAccess Vascular and Medline entered a multi-year agreement to co-brand and distribute AVI's next-generation HydroMID and HydroPICC catheters, which received FDA anti-thrombogenic indication. The partnership leverages Medline's distribution network including more than 1,600 Prime Vendor customers and 300+ acute care reps to rollout co-branded products starting late 2026. The agreement combines AVI's proprietary hydrogel technology designed to reduce catheter-related thrombosis and occlusion complications with Medline's supply chain and customizable kitting capabilities, targeting a vascular access catheter market exceeding $600 million.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Access Vascular competitors and assessment
Company assessmentDirect peers
- Teleflex: Teleflex's Arrow brand is a leading PICC and midline catheter franchise directly competing with Access Vascular's HydroPICC and HydroMID in acute care hospitals. Both companies target vascular access clinicians and hospital supply chains with feature-differentiated catheters.
- Cook Medical: Cook Medical's Spectrum Turbo-Exchange PICC and vascular access lines compete with Access Vascular's HydroPICC in hospital infusion therapy. Both companies target interventional and vascular access clinicians with feature-differentiated catheters.
- AngioDynamics: AngioDynamics' BioFlo PICC and midline catheters feature Endexo polymer technology aimed at reducing thrombotic complications, directly paralleling Access Vascular's MIMIX-based anti-thrombogenic claim. They compete in the same hospital accounts on similar value propositions.
- ICU Medical: ICU Medical (which acquired Smiths Medical) offers PICC and midline catheters alongside its infusion therapy portfolio. It is a direct competitor in the vascular access catheter category Access Vascular serves.
- B. Braun Medical: B. Braun's Introcan Safety and vascular access lines directly overlap with Access Vascular's catheter offerings in acute care settings. Both companies target hospital formularies and compete on safety and complication-reduction claims.
- Terumo Medical: Terumo's SurFlash and other PICC/midline products directly compete with Access Vascular's HydroPICC and HydroMID in the US acute care market. Both companies focus on insertion performance and complication-reduction messaging to vascular access teams.
Broad incumbents
- Becton Dickinson (BD): BD is a dominant incumbent in vascular access devices (PowerPICC, Bard PICC/midline lines) with broad hospital coverage and GPO contracts. It competes head-on with Access Vascular in PICC and midline while offering a much larger portfolio across vascular access and infusion.
- Baxter International: Baxter, post its Vantive kidney-care and infusion-therapy portfolio, competes in adjacent vascular access and infusion delivery categories to Access Vascular. It is a broad incumbent serving many of the same acute care hospital customers through GPO contracts.
Emerging players
- Merit Medical Systems: Merit Medical offers vascular access and drainage catheters with selected feature differentiation. While broader than Access Vascular's niche, it competes in some of the same hospital accounts and represents an emerging challenge in the complication-reduction catheter segment.
Others
- Medline: Medline is Access Vascular's primary distribution partner under the multi-year co-branded agreement announced June 2026. While not a direct competitor in catheter manufacturing, Medline is the dominant US medical supply distributor and effectively controls Access Vascular's primary go-to-market channel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Access Vascular social profiles
Digital presenceAccess Vascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Access Vascular leadership team
Management profileNumber of profiles
Profiles5 records
Access Vascular funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Access Vascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Access Vascular
What does Access Vascular do?
Access Vascular manufactures and sells proprietary vascular access catheters (HydroPICC and HydroMID) built on its patented MIMIX hydrophilic biomaterial platform. The catheters are FDA-cleared with an anti-thrombogenic indication and are designed to reduce catheter-related complications such as thrombosis, occlusions, and infections compared to standard polyurethane devices. The company sells to acute care hospitals and health systems through direct sales and a Medline distribution partnership.
Is Access Vascular a public or private company?
Access Vascular is a private company. It is classified as venture growth investor backed and is currently operating.
When was Access Vascular founded?
Access Vascular was founded in 2015. It employs 11 to 50 people.
Where is Access Vascular based?
Access Vascular is headquartered in Bedford, United States, in the North America region.
How does Access Vascular make money?
One revenue line is on record: medical Device Sales.
Who are Access Vascular's main competitors?
Direct peers on record are Teleflex, Cook Medical, AngioDynamics, ICU Medical, B. Braun Medical and Terumo Medical. Broad incumbents are Becton Dickinson (BD) and Baxter International. Merit Medical Systems is listed as an emerging player. Medline is listed as an others.
Does Access Vascular have an API?
No public API is recorded for Access Vascular.
What industry is Access Vascular in?
Access Vascular's product category is Vascular Access Medical Devices. Its primary akta.pro industry code is HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories), with a secondary code of HLAHAIAH, Infusion Sets, Catheters & Pump Consumables. Its NAICS code is 339112 and its SIC code is 3841.